Abstract:Urinary CXCL10/creatinine (uCXCL10/Cr) is an effective biomarker in pediatric kidney transplant recipients for reliably identifying kidney allograft inflammation. This study modelled the clinical implementation of this test and supported a two‐test approach to reliably exclude other clinically identifiable sources of inflammation, for kidney biopsy indication to rule‐out subclinical rejection. Background Urinary CXCL10/creatinine (uCXCL10/Cr) is proposed as an effective biomarker of subclinical rejection in pediatric kidney transplant recipients. This study objective was to model implementation in the clinical setting. Methods Banked urine samples at a single center were tested for uCXCL10/Cr to validate published thresholds for rejection diagnosis (>80% specificity). The positive predictive value (PPV) for rejection diagnosis for uCXCL10/Cr‐indicated biopsy was modeled with first‐positive versus two‐test‐positive approaches, with accounting for changes associated with urinary tract infection (UTI), BK and CMV viremia, and subsequent recovery. Results Seventy patients aged 10.5 ± 5.6 years at transplant (60% male) had n = 726 urine samples with n = 236 associated biopsies (no rejection = 167, borderline = 51, and Banff 1A = 18). A threshold of 12 ng/mmol was validated for Banff 1A versus no‐rejection diagnosis (AUC = 0.74, 95% CI = 0.57–0.92). The first‐positive test approach (n = 69) did not resolve a clinical diagnosis in 38 cases (55%), whereas the two‐test approach resolved a clinical diagnosis in the majority as BK (n = 17/60, 28%), CMV (n = 4/60, 7%), UTI (n = 8/60, 13%), clinical rejection (n = 5/60, 8%), and transient elevation (n = 18, 30%). In those without a resolved clinical diagnosis, PPV from biopsy for subclinical rejection is 24% and 71% (p = .017), for first‐test versus two‐test models, respectively. After rejection treatment, uCXCL10/Cr level changes were all concordant with change in it‐score. Sustained uCXCL10/Cr after CMV and BK viremia resolution was associated with later acute rejection. Conclusions Urinary CXCL10/Cr reliably identifies kidney allograft inflammation. These data support a two‐test approach to reliably exclude other clinically identifiable sources of inflammation, for kidney biopsy indication to rule out subclinical rejection.

Detection of Subclinical Rejection in Pediatric Kidney Transplantation: Current and Future Practices

Prediction of Subclinical Renal Allograft Rejection by Vascular Endothelial Growth Factor in Serum and Urine.

Rejection markers in kidney transplantation: do new technologies help children?

Biomarkers for Renal Transplantation: Where Are We?

Immune monitoring in pediatric kidney transplant

Developing Renal Allograft Surveillance Strategies – Urinary Biomarkers of Cellular Rejection

Non-invasive biomarkers of acute rejection in pediatric kidney transplantation: New targets and strategies

Subclinical rejection and allograft survival in kidney transplantation: protocol for a systematic review and meta-analysis

Preliminary Investigation of the Biomarkers of Acute Renal Transplant Rejection Using Integrated Proteomics Studies, Gene Expression Omnibus Datasets, and RNA Sequencing.

Urine CXCL10 as a biomarker in kidney transplantation

Optimizing the approach to monitoring allograft inflammation using serial urinary CXCL10/creatinine testing in pediatric kidney transplant recipients

Tackling Chronic Kidney Transplant Rejection: Challenges and Promises

Molecular immune monitoring in kidney transplant rejection: a state-of-the-art review

Prognostic Value of the Donor-Derived Cell-Free DNA Assay in Acute Renal Rejection Therapy: A Prospective Cohort Study.

Tissue, Plasma and Urine MicroRNAs Compared to Protocol Biopsy Histology

“Pre-Histologic” Antibody-Mediated Rejection Detected by Donor-Derived Cell-Free DNA and a Novel Tissue Gene Expression Assay: A Case Report

Subthreshold rejection activity in many kidney transplants currently classified as having no rejection

Progress in Noninvasive Surveillance for Acute Rejection in Pediatric Heart Transplant Recipients: A Real‐World Analysis of Donor‐Derived Cell‐Free DNA‐Based Surveillance Protocol

A gentler approach to monitor for heart transplant rejection

Subclinical rejection-free diagnostic after kidney transplantation using blood gene expression

Advancing kidney transplant outcomes: the role of urinary proteomics in graft function monitoring and rejection detection